Clinical analysis of EGFR ‐positive non‐small cell lung cancer patients treated with first‐line afatinib: A Nagano Lung Cancer Research Group

ConclusionIn real ‐world clinical practice, first‐line afatinib was well managed and was equally as effective as in previous clinical trials ofEGFR‐positive NSCLC. BSA is considered a predictive marker for appropriate afatinib dose reduction.

Source: Thoracic Cancer - April 19, 2019 Category: Cancer & Oncology Authors: Kei Sonehara, Takashi Kobayashi, Kazunari Tateishi, Nobutoshi Morozumi, Fumiaki Yoshiike, Tsutomu Hachiya, Yasushi Ono, Keiichirou Takasuna, Toshihiko Agatsuma, Takeshi Masubuchi, Akemi Matsuo, Hozumi Tanaka, Akio Morikawa, Masayuki Hanaoka, Tags: ORIGINAL ARTICLE Source Type: research